Concomitant t(8;21) and trisomy 4 in a patient with Acute

Myeloid Leukemia (AML) by Phan CL, et al.
Med & Health 2010; 5(1): 45-48 
 
 
45 
 
CASE REPORT
 
Concomitant t(8;21) and Trisomy 4 in a Patient with Acute 
Myeloid Leukemia (AML)  
 
Phan CL1, Ong TC1, Chang KM1, Zubaidah Z2, Puteri Jamilatul NMB2 
 
1  Clinical Hematology Laboratory, Department of Hematology, Hospital Ampang, Jalan 
Mewah Utara, Pandan Mewah, 68000 Ampang, Selangor, Malaysia 
2 Hematology Unit, Cancer Research Center (CaRC), Institute for Medical Research 
(IMR), Jalan Pahang 50588 Kuala Lumpur, Wilayah Persekutuan, Malaysia 
 
 
ABSTRAK 
 
Aberasi t(8;21)(q22;q22) kerap berlaku pada leukemia myeloid akut (18-20%) dan se-
lalunya dikaitkan dengan sub-jenis ‘French-America-British (FAB) M2’. Aberasi trisomi 
4 jarang berlaku dan ia adalah keabnormalan spesifik yang berlaku pada AML M2 atau 
M4. Kami melaporkan satu kajian kes daripada seorang wanita berumur 33 tahun di 
mana diagnosa klinikal dan laporan hematologi menunjukkan leukemia promyelosit 
akut (APL). Ujian sitogenetik pesakit menunjukkan keabnormalan kromosom melibat-
kan aberasi t(8;21) dan trisomi kromosom 4. Kehadiran trisomi 4 dengan t(8;21) dalam 
kes AML jarang berlaku. Kehadiran trisomi 4 dengan t(8;21) tidak mempunyai signifi-
kan yang jelas tetapi ia berkait dengan prognosis yang kurang baik. 
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ABSTRACT  
 
The t(8;21)(q22;q22) is a frequently occurring aberration in acute myeloid leukemia 
(AML) (18-20%) and usually correlate with French-America-British (FAB) M2 subtype.  
Several studies showed that patients carrying this abnormality demonstrated good 
response to standard chemotherapy but also have a high incidence of disease relapse. 
Trisomy 4 is a rare and specific chromosomal abnormality occurring in AML M2 or M4 
of the FAB subtypes. We report a case of a 33-year-old female with an apparently 
clinical and hematologic diagnosis of acute promyelocytic leukemia (APL) in whom 
cytogenetic analysis revealed an abnormal karyotype with trisomy 4, in addition to 
t(8;21). Trisomy 4 and t(8;21) in a patient with AML is rare. The significance of t(8;21) 
with trisomy 4 in AML are unclear but patients bearing this abnormality are associated 
with a poor prognosis. 
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INTRODUCTION 
 
The t(8;21)(q22;q22) is a frequently oc-
curring aberration in acute myeloid leu-
kemia (AML) (18-20%), and usually cor-
relates with the French-America-British 
(FAB) M2 subtype (Shinagawa et al. 
1999). The translocation involves the 
RUNX1 gene on chromosome 21q22 and 
the RUNX1T1 gene on chromosome 
8q22. The translocation resulted in fusion 
of transcripts RUNX1/RUNX1T1 on the 
derivative of chromosome 8. It is re-
ported that patients with AML carrying 
the t(8;21)(q22;q22) exhibit good re-
sponse to chemotherapy with a high re-
mission rate and long-term disease-free 
survival. However, it may be associated 
with a high incidence of early relapse in 
some cases (Shinagawa et al. 1999). 
Trisomy 4 is a recurrent but rare chromo-
some abnormality which appears to oc-
cur in a broad range of hematologic ma-
lignancies, mainly cases of AML with 
FAB M2 and M4 subtypes, and some 
cases with M1 and M5 subtypes (Kwong 
et al. 1993; Shinagawa et al. 1999; 
Beghini et al. 2000). Trisomy 4 could also 
be secondary to an environmental 
mutagen or drug exposure (Shinagawa 
et al. 1999; Nishii et al. 2003). It may also 
present with a sole cytogenetic abnor-
mality or concomitantly with other aber-
rations. The significance of its occur-
rence is still undefined. 
 
CASE REPORT  
 
We report a case of a 33-year-old female 
presenting with fever and anemia. Her 
full blood picture (FBP) showed pancyto-
penia. The morphology of the circulating 
blasts showed presence of Auer rods 
with hypergranulation. Full blood count 
showed a white blood cell (WBC) count 
of 2.3 × 109 /L, with a hemoglobin (Hb) 
concentration of 6.4 g/L and a platelet 
count of  37× 109 /L. There was no his-
tory of long term medication and toxic 
chemical exposure. She was suspected 
as having AML, FAB M3 (APL). How-
ever, the bone marrow aspirate (BMA) 
was reported as only AML. BMA was 
sent for cytogenetic analysis to confirm 
the diagnosis. A trans-retinoic acid 
(ATRA) regimen was given to her as the 
initial treatment. She died soon after the 
diagnosis. 
 
CYTOGENETICS ANALYSIS 
 
Chromosome analysis of bone marrow 
aspirate was performed using the stan-
dard cytogenetic protocol. The karyotype 
was described according to the Interna-
tional System for Human Cytogenetic 
Nomenclature (Shaffer & Tommerup 
2005). Thirteen metaphases were ana-
lysed. Cytogenetic analysis demon-
strated 46,XX,+4, t(8;21)(q22;q22) (Fig-
ure 1). This finding excluded the diagno-
sis of AML M3, but indicated that the pa-
tient is having AML with trisomy 4 in ad-
dition to t(8;21). 
 
DISCUSSION 
 
The t(8;21)(q22;q22) AML present at di-
agnosis is associated with a better prog-
nosis and generally demonstrated pro-
longed disease-free survival (Nishii et al. 
2003). AML with the t(8;21) is frequently 
associated with a loss of sex chromo-
some Y in males and an inactive X in fe-
males, and 3.4% of the cases are variant 
translocations (Shinagawa et al. 1999; 
Nishii et al. 2003). A case of FAB M2 
subtype with anomalies, complex trans-
location of t(6;21;8) and trisomy 4 have 
been reported. However, the presence of 
trisomy 4 has not demonstrated any in-
fluence in clinical prognosis (Shinagawa 
et al. 1999).  
Aberrations in chromosome 7 and 
chromosome 8 are reported to be asso-
ciated with secondary AML or during 
clonal progression of AML (Beghini et al. 
2000; Trivedi et al. 2008). Trisomy 4 is 
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Figure 1: Chromosome rearrangements of t(8;21)(q22;q22) and trisomy 4 (arrows) 
 
rarely reported as the abnormality in AML 
(<1%) (Trivedi et al. 2008). Nishii et al. 
(2003) showed that t(8;21) AML with 
trisomy 4 is very rare. Out of 94 cases, 
only three were found to have concomi-
tant aberrations of t(8;21) with trisomy 4 
(3.2%) (Nishii et al. 2003). t(8;21) AML 
with trisomy 4 has a poor prognosis and 
was speculated that the presence of KIT 
mutation may be responsible for the ad-
verse effect of the disease (Langabeer et 
al. 2003; Trivedi et al. 2008). Few studies 
have demonstrated that patients with the 
t(8;21) and a trisomy 4 showed a signifi-
cantly high frequency of KIT mutation 
(10%) than patients with normal and 
complex aberrant karyotype (Shimada et 
al. 2006). Patients with activation of KIT 
gene have been shown to confer drug 
resistance, which could explain the rela-
tively poor prognosis (Beghini et al. 2000; 
Langabeer et al. 2003; Shimada et al. 
2006). KIT is localized at chromosome 
4q12, thus trisomy 4 leads to an increased 
gene dosage of KIT. It is believed that the 
occurrence of t(8;21) represents the initial 
step to initiate the disease, followed by 
activation of KIT pathway that promotes 
disease progression (Beghini et al. 2000; 
Shimada et al. 2006).  
In our case, the patient apparently had 
clinical and hematological features sug-
gestive of acute promyelocytic leukemia 
(APML) in whom the cytogenetic analysis 
revealed the presence of trisomy 4 with an 
additional t(8;21) hence, excluding the di-
agnosis of APML. Inclusion of cytogenetic 
analysis in addition to clinical and morpho-
logical criteria will produce a reliable clinical 
diagnosis of the disease. This is because 
of variable morphology due to the presence 
of complex or additional chromosomal al-
teration, also the multiple genetic events 
which may affect the various maturation 
stages of cells. Thus, cytogenetic analysis 
is one of the useful tools to confirm the 
clinical diagnosis. Detection of the t(8;21) 
can be further investigated with florescence 
in situ hybridization (FISH)  analysis to de-
termine the AML1 gene rearrangement. 
Other diagnostic tests include immunophe-
notyping which may help to identify the 
subtype of t(8;21) AML. 
A study by Nishii et al. (2003) reported 
that most of the cells carrying trisomy 4 
showed low expressions of CD19 and IL-
17 receptor, and high expressions of 
CD33, CD18, and CD 56 when com-
pared to t(8;21) AML without other addi-
tional chromosomal abnormality (Nishii et 
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al. 2003). CD56 expression in AML is 
reported in multidrug resistance (Trivedi 
et al. 2008). There was no flow cytomet-
ric analysis done in our case. Therefore, 
we cannot explain the relation between 
CD56 expression and trisomy 4 in t(8;21) 
AML.  
 In conclusion, the present case of AML 
FAB M2 is a rare case in terms of cyto-
genetic findings. Concomitant t(8;21) with 
trisomy 4 may constitute a distinctive 
subtype of t(8;21) AML (Nishii et al. 
2003). Hence the acquisition of trisomy 4 
in AML with AML1 rearrangement might 
promote disease progression and an 
unfavourable prognosis. This case illu-
strated the essential roles of cytogenetics 
studies in confirming the diagnosis. Cy-
togenetics analysis provides simultane-
ous analysis of genetic rearrangements 
within leukemic cell. Meanwhile FISH 
analysis approached is a complementary 
test for conventional cytogenetics that 
helps to determine the chromosomal 
rearrangements such as t (8;21), t(15;17) 
and inv(16) in AML cases. 
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